Omega Therapeutics, Inc.: going-concern / distress — Omega Therapeutics files for Chapter 11 bankruptcy with $9.8M DIP financing

Omega Therapeutics, Inc.

Filed voluntary Chapter 11 petition on February 10, 2025 in Delaware Bankruptcy Court.
Received interim approval for $9,820,908 DIP facility from Flagship affiliate; $3,931,953 funded Feb 13.
DIP includes roll-up of $1,475,178 prepetition note plus $165,000 fees; 10% interest, matures 70 days post-petition.
Court-approved milestones: final DIP order by day 30; asset sale order by day 60; closing by day 70.
Company remains debtor-in-possession; Flagship entities are significant stockholders.

Key facts

Extracted from this filing and checked against the source text.

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.9

Omega Therapeutics, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2025-02-10).

Proceeding: chapter 11
Court: United States Bankruptcy Court for the District of Delaware
Petition: 2025-02-10

Exact text from the filing

On February 10, 2025 (the “Petition Date”), Omega Therapeutics, Inc. (the “Company” or “Debtor”) commenced a chapter 11 case (the “Chapter 11 Case”) as debtor in possession in a voluntary proceeding under Chapter 11 of the United States Code

View on SEC.gov

Browse all distress & bankruptcy →

Source: SEC EDGAR

accession 0001193125-25-027349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.